SALT LAKE CITY, USA, June 1 2017 — LSK Biopharma (LSKB Company) will be attending the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, USA from June 2-6. The Company will be meeting with leading oncologists and key opinion leaders from across the globe to discuss late stage development of apatinib mesylate, the Company’s clinically proven angiogenesis inhibitor.

The Company also sponsored a ‘Trials in Progress’ poster (Abstract ID: TPS4138) which is scheduled to be presented on Saturday, June 3rd from 8:00am to 11:30am Central Time. Additional information will be available at the poster session or by appointment